Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Trefoil factors peptide-3 is associated with residual invasive breast carcinoma following neoadjuvant chemotherapy ; volume:19 ; number:1 ; day:11 ; month:2 ; year:2019 ; pages:1-12 ; date:12.2019
BMC cancer ; 19, Heft 1 (11.2.2019), 1-12, 12.2019
- Urheber
-
Al-Salam, Suhail
Sudhadevi, Manjusha
Awwad, Aktham
Al Bashir, Mohamed
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-5316-y
- URN
-
urn:nbn:de:101:1-2019031321571900766058
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Al-Salam, Suhail
- Sudhadevi, Manjusha
- Awwad, Aktham
- Al Bashir, Mohamed
- SpringerLink (Online service)
Ähnliche Objekte (12)
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI
Neoadjuvant chemotherapy in locally advanced invasive lobular carcinoma: A limited institutional experience
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Cytomorphological Disparities in Invasive Breast Cancer Cells following Neoadjuvant Endocrine Therapy and Chemotherapy
Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer
The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy
Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy
Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI
Neoadjuvant chemotherapy in locally advanced invasive lobular carcinoma: A limited institutional experience
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Cytomorphological Disparities in Invasive Breast Cancer Cells following Neoadjuvant Endocrine Therapy and Chemotherapy
Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer
The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy
Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy
Criteria for identifying residual tumours after neoadjuvant chemotherapy of breast cancers: a magnetic resonance imaging study
Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients
Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
Evaluating residual tumor after neoadjuvant chemotherapy for muscle-invasive urothelial bladder cancer: diagnostic performance and outcomes using biparametric vs. multiparametric MRI
Neoadjuvant chemotherapy in locally advanced invasive lobular carcinoma: A limited institutional experience
Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Cytomorphological Disparities in Invasive Breast Cancer Cells following Neoadjuvant Endocrine Therapy and Chemotherapy
Oncologic necessity for the complete removal of residual microcalcifications after neoadjuvant chemotherapy for breast cancer
The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy
Targeting mTOR and DNA repair pathways in residual triple negative breast cancer post neoadjuvant chemotherapy
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy
Targeted axillary dissection reduces residual nodal disease in clinically node- positive breast cancer after neoadjuvant chemotherapy